These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 31147187)

  • 1. Effects of a fully magnetically levitated centrifugal-flow or axial-flow left ventricular assist device on von Willebrand factor: A prospective multicenter clinical trial.
    Bansal A; Uriel N; Colombo PC; Narisetty K; Long JW; Bhimaraj A; Cleveland JC; Goldstein DJ; Stulak JM; Najjar SS; Lanfear DE; Adler ED; Dembitsky WP; Somo SI; Crandall DL; Chen D; Connors JM; Mehra MR
    J Heart Lung Transplant; 2019 Aug; 38(8):806-816. PubMed ID: 31147187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of von Willebrand factor with a fully magnetically levitated centrifugal continuous-flow left ventricular assist device in advanced heart failure.
    Netuka I; Kvasnička T; Kvasnička J; Hrachovinová I; Ivák P; Mareček F; Bílková J; Malíková I; Jančová M; Malý J; Sood P; Sundareswaran KS; Connors JM; Mehra MR
    J Heart Lung Transplant; 2016 Jul; 35(7):860-7. PubMed ID: 27435529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure.
    Uriel N; Colombo PC; Cleveland JC; Long JW; Salerno C; Goldstein DJ; Patel CB; Ewald GA; Tatooles AJ; Silvestry SC; John R; Caldeira C; Jeevanandam V; Boyle AJ; Sundareswaran KS; Sood P; Mehra MR
    Circulation; 2017 May; 135(21):2003-2012. PubMed ID: 28385948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired von Willebrand factor deficiency is reduced in HeartMate 3 patients†.
    Klaeske K; Dieterlen MT; Scholz U; Lehmann S; Garbade J; Fischer J; Jawad K; Borger MA; Meyer A
    Eur J Cardiothorac Surg; 2019 Sep; 56(3):444-450. PubMed ID: 30815698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Clinical Outcomes With Left Ventricular Assist Device Use by Bridge to Transplant or Destination Therapy Intent: The Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) Randomized Clinical Trial.
    Goldstein DJ; Naka Y; Horstmanshof D; Ravichandran AK; Schroder J; Ransom J; Itoh A; Uriel N; Cleveland JC; Raval NY; Cogswell R; Suarez EE; Lowes BD; Kim G; Bonde P; Sheikh FH; Sood P; Farrar DJ; Mehra MR
    JAMA Cardiol; 2020 Apr; 5(4):411-419. PubMed ID: 31939996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device.
    Meyer AL; Malehsa D; Budde U; Bara C; Haverich A; Strueber M
    JACC Heart Fail; 2014 Apr; 2(2):141-5. PubMed ID: 24720921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospitalization Patterns and Impact of a Magnetically-Levitated Left Ventricular Assist Device in the MOMENTUM 3 Trial.
    Vidula H; Takeda K; Estep JD; Silvestry SC; Milano C; Cleveland JC; Goldstein DJ; Uriel N; Kormos RL; Dirckx N; Mehra MR
    JACC Heart Fail; 2022 Jul; 10(7):470-481. PubMed ID: 35772857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Analysis of Stroke in the Long-Term Cohort of the MOMENTUM 3 Study.
    Colombo PC; Mehra MR; Goldstein DJ; Estep JD; Salerno C; Jorde UP; Cowger JA; Cleveland JC; Uriel N; Sayer G; Skipper ER; Downey FX; Ono M; Hooker R; Anyanwu AC; Givertz MM; Mahr C; Topuria I; Somo SI; Crandall DL; Horstmanshof DA
    Circulation; 2019 Jan; 139(2):155-168. PubMed ID: 30586698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do patients with the centrifugal flow HeartMate 3 or HeartWare left ventricular assist device have better outcomes compared to those with axial flow HeartMate II?
    Florisson DS; Conte SM; De Bono JA; Newcomb AE
    Interact Cardiovasc Thorac Surg; 2019 Dec; 29(6):844-851. PubMed ID: 31436825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare Resource Use and Cost Implications in the MOMENTUM 3 Long-Term Outcome Study.
    Mehra MR; Salerno C; Cleveland JC; Pinney S; Yuzefpolskaya M; Milano CA; Itoh A; Goldstein DJ; Uriel N; Gulati S; Pagani FD; John R; Adamson R; Bogaev R; Thohan V; Chuang J; Sood P; Goates S; Silvestry SC
    Circulation; 2018 Oct; 138(18):1923-1934. PubMed ID: 29807933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early outcomes with durable left ventricular assist device replacement using the HeartMate 3.
    Barac YD; Wojnarski CM; Junpaparp P; Jawitz OK; Billard H; Daneshmand MA; Agrawal R; Devore A; Patel CB; Schroder JN; Milano CA
    J Thorac Cardiovasc Surg; 2020 Jul; 160(1):132-139.e1. PubMed ID: 31740114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced continuous-flow left ventricular assist device speed does not decrease von Willebrand factor degradation.
    Kang J; Zhang DM; Restle DJ; Kallel F; Acker MA; Atluri P; Bartoli CR
    J Thorac Cardiovasc Surg; 2016 Jun; 151(6):1747-1754.e1. PubMed ID: 26971377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a mathematical model for evaluating shear-induced damage of von Willebrand factor.
    Li Y; Xi Y; Wang H; Sun A; Wang L; Deng X; Chen Z; Fan Y
    Comput Biol Med; 2023 Sep; 164():107379. PubMed ID: 37597407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and clinical correlates of de-novo aortic regurgitation with a fully magnetically levitated left ventricular assist device: a MOMENTUM 3 trial portfolio analysis.
    Uriel N; Milano C; Agarwal R; Lee S; Cleveland J; Goldstein D; Wang A; Crandall D; Mehra MR
    Eur J Heart Fail; 2023 Feb; 25(2):286-294. PubMed ID: 36404406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time course of acquired von Willebrand disease associated with two types of continuous-flow left ventricular assist devices: HeartMate II and CircuLite Synergy Pocket Micro-pump.
    Goda M; Jacobs S; Rega F; Peerlinck K; Jacquemin M; Droogne W; Vanhaecke J; Van Cleemput J; Van den Bossche K; Meyns B
    J Heart Lung Transplant; 2013 May; 32(5):539-45. PubMed ID: 23570742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased RPM reduces von Willebrand factor degradation with the EVAHEART LVAS: implications for device-specific LVAD management.
    Bartoli CR; Kang J; Motomura T
    J Card Surg; 2020 Jul; 35(7):1477-1483. PubMed ID: 32652785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left Ventricular Assist Device Design Reduces von Willebrand Factor Degradation: A Comparative Study Between the HeartMate II and the EVAHEART Left Ventricular Assist System.
    Bartoli CR; Kang J; Zhang D; Howard J; Acker M; Atluri P; Motomura T
    Ann Thorac Surg; 2017 Apr; 103(4):1239-1244. PubMed ID: 27717422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of von Willebrand factor profiles in pulsatile and continuous left ventricular assist device recipients.
    Crow S; Milano C; Joyce L; Chen D; Arepally G; Bowles D; Thomas W; Ortiz NV
    ASAIO J; 2010; 56(5):441-5. PubMed ID: 20613494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro comparison of the hemocompatibility of two centrifugal left ventricular assist devices.
    Zayat R; Moza A; Grottke O; Grzanna T; Fechter T; Motomura T; Schmidt-Mewes C; Breuer T; Autschbach R; Rossaint R; Goetzenich A; Bleilevens C
    J Thorac Cardiovasc Surg; 2019 Feb; 157(2):591-599.e4. PubMed ID: 30414772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF: A Multicenter Study.
    Netuka I; Sood P; Pya Y; Zimpfer D; Krabatsch T; Garbade J; Rao V; Morshuis M; Marasco S; Beyersdorf F; Damme L; Schmitto JD
    J Am Coll Cardiol; 2015 Dec; 66(23):2579-2589. PubMed ID: 26670056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.